Latest & greatest articles for prostate cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer screening

101. An economic rationale for prostate cancer screening

An economic rationale for prostate cancer screening An economic rationale for prostate cancer screening An economic rationale for prostate cancer screening Benoit R M, Naslund M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health (...) technology (a) Screening for prostate cancer using prostate-specific antigen(PSA) testing with and without digital rectal examination(DRE) (b) Screening for breast cancer using mammography with and without clinical breast examination. Type of intervention Secondary prevention Economic study type Cost-effectiveness analysis. Study population Men aged 50 to 70 and women aged 50-69. Setting The practice setting for breast cancer screening was not specified (it might be primary care). Prostate cancer

1994 NHS Economic Evaluation Database.